Gitte S. Hansen

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Theory-based process evaluation of a non-randomised single-arm pilot study investigating time-restricted eating in the treatment of type 2 diabetes-the RESET2 pilot study.

Theory-based process evaluation of a non-randomised single-arm pilot study investigating time-restricted eating in the treatment of type 2 diabetes-the RESET2 pilot study.

Journal: Pilot and feasibility studies

Published: January 27, 2025

Protocol for a 1-year randomised, controlled, parallel group, open-label trial on the effects and feasibility of time-restricted eating in individuals with type 2 diabetes- The REStricted Eating Time in the treatment of type 2 diabetes (RESET2) trial.

Protocol for a 1-year randomised, controlled, parallel group, open-label trial on the effects and feasibility of time-restricted eating in individuals with type 2 diabetes- The REStricted Eating Time in the treatment of type 2 diabetes (RESET2) trial.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: August 28, 2024

Time-Restricted Eating is a Feasible Dietary Strategy in the Treatment of Complicated Type 2 Diabetes: The RESET2 Pilot Study.

Time-Restricted Eating is a Feasible Dietary Strategy in the Treatment of Complicated Type 2 Diabetes: The RESET2 Pilot Study.

Journal: Journal of nutrition education and behavior

Published: April 16, 2024

The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.

The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.

Journal: Molecular metabolism

Published: August 10, 2018

Pancreatic β-Cell Rest Replenishes Insulin Secretory Capacity and Attenuates Diabetes in an Extreme Model of Obese Type 2 Diabetes.

Pancreatic β-Cell Rest Replenishes Insulin Secretory Capacity and Attenuates Diabetes in an Extreme Model of Obese Type 2 Diabetes.

Journal: Diabetes

Published: March 14, 2018

Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.

Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.

Journal: Physiology & behavior

Published: November 15, 2017

GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice.

GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice.

Journal: Journal of peptide science : an official publication of the European Peptide Society

Published: May 22, 2017

The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice.

The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice.

Journal: Journal of diabetes research

Published: November 08, 2015

A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents.

A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents.

Journal: PloS one

Published: April 14, 2015

The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.

The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.

Journal: The Journal of pharmacology and experimental therapeutics

Published: July 05, 2014

The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.

The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.

Journal: European journal of pharmacology

Published: April 15, 2014

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

Journal: The Journal of clinical investigation

Published: February 24, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026